Consistently, the co-knockdown of FANCD2 and POLQ in two lung cancer cell lines resulted in hypersensitivity to cisplatin, as compared with the single knockdown of FANCD2 or POLQ [58]. Here, FANCD2 is linked to lung carcinoma.